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Introduction:Sensitive neuropsychological tests areneeded to improvepower for clin-
ical trials in early Alzheimer’s disease (AD).
Methods: To develop a neuropsychological composite (FLAME – Factors of Longitudi-
nal Attention,Memory and Executive Function), we assessed, 10,714 participants over
the age of 50 from PROTECT with validated computerized assessments for 2 years. A
factorial analysis was completed to identify the key cognitive factors in all participants,
and further analyses examined sensitivity to change in people with stage 2/3 early
Alzheimer’s disease (AD) according to the US Food and Drug Administration (FDA)
framework.
Results: The FLAME composite score (speed of attention, accuracy of attention, mem-
ory, and executive function) distinguished between normal cognition and stage 2/3
early AD at baseline, and was sensitive to cognitive and global/functional decline over
2 years, with the potential to improve power for clinical trials.
Discussion: FLAME is sensitive to change, providing a straightforward approach to
reduce sample size for RCTs in early AD.
Conclusion: FLAME is a useful computerized neuropsychology composite with utility
for clinical trials focusing on cognition.
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1 BACKGROUND
There are currently more than 40million people worldwide living with
Alzheimer’s disease (AD) and other dementias, increasing tomore than
100 million by 2050.1 In addition, it is estimated that at least 15% of
people age 60 or above havemild cognitive impairment (MCI), and that
between 8% and 15% of these will progress to dementia each year,
most commonly to AD.2
In the last 20 years there have been only two new licensed phar-
macological therapies for the treatment of AD: memantine3 and
oligomannate4 (available only in China). There are no licensed phar-
macological treatments for MCI. The last decade has seen a number
of high-profile unsuccessful randomized-controlled trials (RCTs) of
amyloid immunotherapy and β-site amyloid precursor protein cleaving
enzyme (BACE) inhibitors.5,6 Although there are more encouraging
emerging results for aducanumab, gantenerumab, and BAN2401,7,8
there are still a very limited number of compounds in phase 2 and
phase 3 clinical trials. Improved clinical trial designs are central to
the treatment development pipeline. Increasingly the consensus
view is that disease-modifying treatments are likely to confer the
greatest benefits in people with early AD or MCI. Although this is
probably correct, it raises significant challenges. Cognitive decline
is often relatively modest and variable at this stage of disease.9 The
most widely used cognitive assessments are not very sensitive to
subtle cognitive deficits; consequently, they require large sample
sizes to confer appropriate power for clinical trials.10 This presents a
major barrier to conducting trials, adding significantly to the time and
cost.
The US Food and Drug Administration (FDA) has taken a helpful
step with their recent guidance for RCTs, focusing on early preclinical
and clinical stages of AD. Within the guidance, early pre-clinical AD is
divided into two groups: stage 2 characterized by subtle impairments
on sensitive neuropsychological assessments in the absence of func-
tional impairment and stage 3 where there are functional impairments
in addition to neuropsychological deficits. The guidelines indicate that
an effective intervention would have a “persuasive effect on sensitive
measures of neuropsychological performance.”11 Computerized neu-
ropsychological assessments could potentially satisfy this expectation
for neuropsychological test sensitivity better than conventional pen
and paper testing. With computerized assessments, test presentation
is more consistent, problems with inter-rater reliability are avoided,
andmillisecond reaction times canbeeasily captured. In addition,many
of the tests are free of learning effects, thereby enabling repeat test-
ing to reduce variability.12-15 Test batteries such as the Cognitive Drug
Research battery and CogTrack, have already been shown to be sen-
sitive to change in trials of cholinesterase inhibitors,16 other trials of
symptomatic drugs,17 evaluation of natural products,18 and RCTs of
cognitive training.15
Important studies from the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) have examined the sensitivity to change of widely used
paper and pencilmeasures such as theMiniMental Status Examination
(MMSE) and Alzheimer’s Disease Assessment Scale–Cognitive Sub-
RESEARCH INCONTEXT
∙ Systematic review: The authors reviewed the liter-
ature using traditional (eg, PubMed) sources and
meeting abstracts/presentations. Several new neu-
ropsychology composites or scoring systems have been
developed (eg, ADCOMS, CatchCog, PACC) and prelim-
inary validation studies indicate improved sensitivity to
change compared to traditional measures. The potential
for a computerized neuropsychological composite to
improve sensitivity to change in cognitive function has not
been systematically examined in longitudinal studies.
∙ Interpretation: Based on a much larger cohort than has
been assessed for other evolving tools, the FLAME neu-
ropsychology composite was evaluated in 10,000 older
people (including 1699 with stage 2/3 early AD - FDA
framework) followed over 2 years. The FLAME compos-
ite had excellent sensitivity to change and the potential
to substantially reduce sample sizes for clinical trials and
compares favorably with other promising composites.
∙ Future directions: Further validation in cohorts assessed
with AD biomarkers will be an important next step.
scale (ADASCog) in peoplewith pre-clinical AD/MCI. A key paper from
Grill et al.,10 focusing on a cohort of 364 people with MCI, identified a
decline in cognition corresponding to a 3.64 point (standard deviation
[SD] 6.76) increase on the ADAS Cog over 2 years. Assuming the same
rate of decline and the same variability, a clinical trial would require
a cohort of 1046 people per treatment arm to give 80% power with
5% significance (two-sided alpha) to detect a 25% treatment effect.
These findings provide an important benchmark against which to test
other measures. Composite neuropsychological scores, both paper
and pencil and computerized, may provide an advantage over single
instruments. Evolving composites include the Preclinical Alzheimer’s
Cognitive Composite (PACC).19-21 Developed to maximize sensitivity
to change in people who are amyloid positive, PACC has reported
encouraging preliminary validation data in a longitudinal cohort of
66 participants.19 Other emerging scales have combined neuropsy-
chology and functional data. Encouraging baseline data for capturing
changes in cognition (CatchCog) have demonstrated good correlation
between a three-factor composite (memory, executive function, instru-
mental activities of daily living) and both informant-reported cognitive
decline and cortical atrophy.20 A 12-month follow-up study has now
been reported, showing moderate to high levels of sensitivity to
change in 131 people assessed longitudinally, although only 24 of the
participants had either subjective cognitive decline orMCI.21 A further
scoring approach, the AD Composite Score (ADCOMS), based on spe-
cific items of commonly used dementia assessments from fourMCI tri-
als demonstrated potentially improved sensitivity over ADAS Cog and
MMSE, although the level of sensitivity was less advantageous for the
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group with amnestic MCI.22 Although these approaches may lead to
valuable composite measures, validation is still relatively preliminary.
The CDR System, Cogstate, and CANTAB23-26 have led the field in
the provision of computerized cognitive testing, but mainly for diag-
nosis (CANTAB26) or for RCTs of symptomatic treatments such as
cholinesterase inhibitors (CDR [eg27]). The COGSTATE28 Brief Bat-
tery (CBB) is being employed in the Brain Health Registry. Initial find-
ings showed that at baseline the sub-group of participants with self-
reported MCI/AD diagnoses from the 6463 subjects age 55 and older
had a poorer performance on the online CBB tests.28 A composite
score from COGSTATE has also been evaluated cross-sectionally in
more than 4000 people from the A4 study of people with presymp-
tomatic familial AD, showing significant but surprisinglymodest differ-
encesbetweenpeoplewhowereamyloidpositive andamyloidnegative
and modest correlations with the PACC paper and pencil composite.29
Longitudinal data have been collected for cognitively normal individu-
als for each of these platforms,23,26,30 but learning effects have been
reported with both COGSTATE and CANTAB,30,31 which could impact
sensitivity to change longitudinally. There are a couple of modest lon-
gitudinal studies with CANTAB that present longitudinal data for 18
monthsor longer inpeoplewith early cognitive impairment. The largest
of these usedCANTAB to assess a cohort including 59 peoplewithMCI
followed for 18 to 24 months as part of a study focusing on subjec-
tive cognitive decline. A number of different evaluation models were
presented, highlighting significantly greater decline in peoplewithMCI
than those with subjective cognitive decline in the absence ofMCI.32
Although there are therefore some encouraging data, the poten-
tial for practice effects with some of the test batteries is a concern,
and larger longitudinal studies in people with MCI and/or early AD
are needed to determine sensitivity to change in these individuals
across core cognitive domains. The key question of whether comput-
erized neuropsychological assessments could provide amore sensitive
approach to the development of a clinical trial neuropsychology com-
posite for people with early AD or MCI requires more evidence from
larger longitudinal studies that include at-risk populations and assess
core aspects of cognitive function.24
The current study examines 2 years of cognitive data derived from
detailed computerized neuropsychological evaluation of more than
10,000 people over the age of 50, including 1699 with a level of cogni-
tive impairment consistentwith stage2or stage3earlyAD, to optimize
a neuropsychological composite that is sensitive to change.
2 METHODS
2.1 Study design
This study used 2-year longitudinal data from the online Platform
for Research Online to investigate Genetics and Cognition in Ageing
(PROTECT) study of people over the age of 50 without a clinical
diagnosis of dementia (http://www.protectstudy.org.uk/), launched
in November 2015. PROTECT was publicized through media part-
nerships, and interested members of the public were able to consent
and join the program through the study website. The study received
ethical approval from the UK London Bridge National Research Ethics
Committee (Ref: 13/LO/1578). Enrollment was completed via the
study website following national publicity and signposting through
partner cohorts and organizations. Participants gave electronic
informed consent through an online registration process. PROTECT
has over 28,000 participants, and is a 10-year cohort study that allows
nested clinical trials, with the main study participants undertaking
annual assessments. At the time the current study commenced there
were 14,201 participants. The current article reports the 10,714
participants who enrolled in a longitudinal sub-study focusing on
enhanced assessment of cognition. The participants in the current
study were representative of the overall study population33
2.2 Data collection
All participants completed a series of online self-report questionnaires
annually. This included demographic information (date of birth, gen-
der, highest level of education) and a self-rated assessment of global
change (including function) using the InformantQuestionnaire onCog-
nitiveDecline in the Elderly (IQCODE).34,35 Although the primary eval-
uationwas undertaken using the self-report scale, informant datawere
available for 4562 participants, which showed 94% concordance in the
classification of participants.
Two online neuropsychological test batteries were completed
(PROTECT and CogTrack), incorporating widely used and well-
validated neuropsychology tests utilized by large commercial test
batteries such as the CDR system. The tests of executive function
(Verbal Reasoning),15,36,25 Attention (Simple Reaction Time, Choice
Reaction Time, Digit Vigilance),37,38,18 Working Memory (Paired
Associate Learning15,39 Self-Ordered Search,15,39 Digit Span),15,40 and
Episodicmemory (Delayed Picture Recognition)41,18,42 have been used
widely over the last 35 years. The importance here is that the tests
employed on PROTECT use the previously published test paradigms.
The tests and the key outputs are described in Table 1. The online
cognitive assessments take approximately 30minutes to complete and
were undertaken at baseline and annually for 2 years. Through the use
of parallel forms and increased sessions the tests have minimal learn-
ing effects,12 an important issue in cognitive testing.13,14 The partici-
pantswere asked to complete the test batteries three timesover7days
annually (leaving 24 h between each session). We have demonstrated
previously that there are minimal learning effects with six repeats of
the tests, and that this substantially reduces variability.12
3 THRESHOLDS FOR FDA STAGE 2 AND STAGE
3 EARLY AD
The FDA guidelines describe stage 2 and stage 3 early AD as pre-
dementia stages of the disease.11 Stage 2 in the FDA guideline
describes individuals with neuropsychological impairments on sensi-
tive testing in the absence of functional impairments. The FDA paper
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TABLE 1 Neuropsychological test descriptions and outcomemeasures contributing to composites
Task Description
PROTECTCore Neuropsychological Tests
Self-ordered search Total score (Memory) 5Minutes
Average
b
A series of boxes are present on the screen; one of the boxes
will contain a diamond. The volunteer selects each box until
they locate the diamond. The diamond is then placed in
another box and again the volunteermust locate it, but they
must be careful not to select the box in which the diamond
was previously found. Higher scores are achieved through




Total score (Memory) 3Minutes
Average
b
A series of objects appear in the cells on screen. The volunteer
is instructed to remember the cell in which the object
appears.When an object appears at the bottom center, the
volunteer is instructed to click on the cell in which they
recall seeing that object. The volunteer is given three
attempts at each level. This taskmeasures workingmemory
and learning.
Digit Span Total score (Memory) 3Minutes
Average
b
Using a ratchet-style approach in which each successful trial is
followed by a new sequence that is one digit longer than the
last and each unsuccessful trial is followed by a new
sequence that is one digit shorter than the last. This task
measures aspects of attention.
Verbal reasoning
tasks
Total Score (executive function)
Median Speed of correct responses
(executive function)
Standard Deviation of correct
responses (executive function)
Accuracy (executive function)
3Minutes A sentence is displayed at the bottom of the screenwhilst a
square and a circle are displayed above. The volunteer needs
to respond as to whether the sentence correctly or
incorrectly describes the configuration of the circle and
square. The taskmeasures verbal/grammatical reasoning.
c
CogTrack Neuropsychological Tests
Digit Vigilance Median Speed of correct responses
(Speed of Attention)
Standard Deviation of correct
responses (Accuracy of Attention)
Accuracy (Accuracy of Attention)
False Alarms (Accuracy of Attention)
3Minutes A target digit from one to nine is randomly selected and
constantly displayed to the right-hand side of the
screen. Digits are then presented one at a time in the center
of the screen. The volunteer is required to respond as
quickly as possible every time a digit matches the target
digit. Correct detections, the speed of the detections and
responsesmade in error (false alarms) are recorded.
Choice Reaction Time Median Speed of correct responses
(Speed of Attention)
Standard Deviation of correct
responses
Accuracy (Accuracy of Attention)
2Minutes The two possible stimuli in this task that can appear on screen.
Equal amounts of each stimuli type will be displayed. The
volunteer is required to respondwith the correct response
key as quickly as possible every time the stimuli appears on






Median Speed of correct responses
(Memory)
Standard Deviation of correct
responses
Accuracy (Memory)
3.5Minutes At the start of the battery 20 pictures are presented for an
equal time on screen. At the end of the battery the original
pictures plus the 20 very similar distractor pictures are
presented one at a time in a counterbalanced order. For
each picture the volunteer has to indicate whether or not it
was the precise picture shown earlier, as quickly and
accurately as possible. Each picture remains on the screen
until a response is made. The accuracy and speed of each
response is recorded.
Simple Reaction Time Median Speed of correct responses
(Speed of Attention)
Standard Deviation of correct
responses
2Minutes The volunteer is required to respond as quickly as possible
when a stimulus is presented in the center of the screen. The
volunteer is informed that the stimuli will be presented one
at a time and that they will remain there until a response is
made. The speed of each response is recorded.
a
This is the time for a single session administration of the test.
b
Timings wise this task is performance driven so can be as short as 1.5minutes.
c
A verbal reasoning taskwas part of both the PROTECT andCogTrack batterywith different presentations and outcomemeasures. TheCogTrack version did
not restrict time for volunteers.
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does not highlight specific tests or thresholds, but implies that it is a
sensitive level of impairment across more than one cognitive domain.
In the current study, stage2wasoperationalized to includeparticipants
who scored>1 SDbelowbenchmarked norms15,43-45 on at least two of
the four PROTECT neuropsychological tests of memory and executive
function (Table 1). Stage 3, requiring people to have neuropsychologi-
cal and subtle functional impairments, was operationalized to include
participants who scored>1.5 SD below benchmarked norms15,43 on at
least two of the four PROTECT tests and had a total IQCODE score
≥64.34 The FDA paper also discusses clinically meaningful outcomes
and the subsequent development of functional impairments in people
at stage 2. The prediction of functional decline in patients at stage 2 is
therefore an important evaluation. As the neuropsychology definition
was a measure of multi-domain impairment, as a sensitivity analysis
further evaluations were also undertaken for amnestic MCI (>1.5 SD
from benchmarked norms in paired associate learning and functional
impairment on IQCODE) and non-amnestic (executive) MCI (>1.5 SD




A principal components analysis (or PCA) together with Varimax rota-
tion was done to identify the factor structure within the neuropsy-
chological tests undertaken using the average baseline data from all
participants. Factors with eigenvalues greater than unity and factor
loadings of 0.4 and above were considered to indicate that a spe-
cific task mapped to an identified factor. The derived composites were
then applied to examine longitudinal decline in people with early AD
(stage 2, stage 3) as a validation cohort (described in the section
below).
4.2 Main analysis
All analyses of longitudinal data were conducted using the R statistical
packageVersion3.6.2MixedModel RepeatedMeasure (MMRM); anal-
yses of variance (ANOVAs) were conducted on the change from base-
line data using unstructured covariance. An IQCODE baseline total
score was fitted as a fixed factor. Age, gender, education, and base-
line performance were fitted as covariates. Participants performed
three sessions over 7 days and average performance was calculated.
The effect sizes were calculated by dividing the least squares mean
differences by the square root of the residual variance from the
MMRM ANOVAs. Cohen’s classification of effect sizes was adopted,
with d = 0.2, d = 0.5, and d = 0.8 indicating the thresholds for small,
medium, and large effects, respectively.46 All scores were normalized
to 0 to 100 range. The total score was determined by calculating the
mean and SD of the four sub-scores, giving a total score also out of
100. The required sample sizes for clinical trials based on this change
were calculated using the Harvard calculator47 (http://hedwig.mgh.
harvard.edu/sample_size/size.html), assuming parallel design with
0.05 significance level, the change SD, power of 0.8 and 25% of mean
difference. Pearson correlations were undertaken to determine the
relationship between change in neuropsychological performance and




Detailed computerized neuropsychological assessments were avail-
able for 10,714 participants at baseline, of whom complete 2-year
follow-up data were available for 8965 individuals (84%). A total of
1078 people with complete follow-up data met the study criteria for
stage 2 early AD at baseline, and 621 individuals met study criteria for
stage 3 early AD at baseline.
The cohort characteristics are described in Table 2.
Seventy-three percent of participants were female, the mean age
was 61.7 (SD 7.13), and 29% of the cohort reported a family history
of dementia. The PCA identified four factors: speed of attention (fac-
tor 1), accuracy of attention (factor 2), memory (factor 3) and executive
function (factor 4) (Table 3).
Each factor was normalized to a maximum score of 100. The base-
line scores for people with normal cognition, stage 2 early AD, and
stage 3 early AD are shown in Table 4. (FLAME: Factors of Longitudi-
nal Attention, Memory and Executive Function).
5.2 Concurrent validity
Participants meeting the criteria for stage 2 early AD and stage 3
early AD showed significantly greater impairment on each of the
four cognitive domains compared to people with normal cognition
(P < 0.0001 for all cognitive domains). There were also significant
differences in global change and function between the groups (early
AD stage 2: average total IQCODE score 50.9 [SD 2.96], average item
score 3.06; early AD stage 3: IQCODE average total score 67.8 [SD
3.12], average item score 4; normal cognition: average total IQCODE
score 23.6 [SD 4.05], average item score 1.31, with P < 0.01 for all
comparisons).
5.3 Longitudinal change over 2 years
For the combined FLAME score and for each cognitive factor, a statis-
tically significant decline in performance over 2 years was observed by
group (stage3earlyAD>stage2earlyAD>normal cognition) (Table 5).
Seventeen percent of peoplewith stage 2 or stage 3 early ADunder-
took regular brain training; the sensitivity to changewas unaltered in a
further analyses excluding these individuals.
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TABLE 2 Sample characteristics
Group Normal Cognition N= 7286 Stage 2 Early ADN= 1081 Stage 3 Early ADN= 621
Gender Female Male Female Male Female Male
N 4473 2813 852 229 492 129
Age, mean (SD) 61.1 (7.1) 63.1 (7.6) 64.9 (7.9) 61.7 (7.2) 64.2 (8.1) 61.4 (7)





























































Group Normal Cognition N= 7286 Stage 2 Early ADN= 1081 Stage 3 Early ADN= 621
Gender Female Male Female Male Female Male
N 4473 2813 852 229 492 129
Agemean (SD) 61.1 (7.1) 63.1 (7.6) 64.9 (7.9) 61.7 (7.2) 64.2 (8.1) 61.4 (7)





























































5.4 Sensitivity to change in stage 2 and stage 3
early AD
Twenty-five percent of the longitudinal change in FLAME score over
2 years was calculated. This enabled an estimated sample size to be
calculated for a 25% treatment effect over 2 years independently for
stage 2 and stage 3 early AD. For a trial with 80%power and requiring a
significance level of 0.05. Using this method, 119 people per treatment
armwouldbe required to achieve this level of power for a trial in people
with stage 2 early AD and 132 people per arm for a trial with this level
of power in people with stage 3 early AD with the FLAME composite
(Table 6).
Sensitivity analyses were undertaken to examine change in people
with amnestic single-domain MCI (1.5 SD below benchmarked norms
on PAL with functional impairment) and non-amnestic (executive) MCI
(1.5 SD below benchmarked norms on grammatical reasoning). To give
80% power to 0.05 level of significance to detect a 25% treatment
effect, 205 people per arm were required for a trial in people with
amnestic MCI and 187 people per armwere required for a trial in peo-
ple with stage executiveMCI (Tables 7 and 8).
5.5 Correlation with functional decline
Over 2 years therewas a highly significant correlation between decline
in neuropsychological performance on the total FLAME composite and
IQCODE score as an indicator of decline in function. There was also
a significant correlation between decline in each of the four individ-
ual cognitive factors in FLAME respectively and worsening function as
indicated by IQCODE (Table 9).
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TABLE 3 Factor analysis of 13 outcomemeasures from the two
neuropsychological batteries
Taskmeasure Factor Number
1 2 3 4
Simple Reaction Time Speed
Median
.84* −.5 .3 −.4
Digit Vigilance Speed .82* −.19 .22 −.10
Choice Reaction Time Speed
Median
.73* −.6 .11 −.5
Verbal Reasoning Accuracy −.4 .86* −.9 .6
Verbal Reasoning Speed −.3 .79* −.11 .9
Verbal Reasoning Total Score −.12 .84* −.15 .24
Delayed Visual Recognition
Accuracy
.13 −.9 .87* −.5
Paired Associate Learning
Total Score
−.5 .4 .78* −.8
Self-Ordered Search Total
Score
−.2 .27 .68* 0
Digit Span Total Score −.8 .11 .67* .10
Choice Reaction Time
Accuracy
.32 .3 .1 .68*
Digit Vigilance Targets
Correctly Detected
−.33 .1 .4 .65*
Digit Vigilance False Positive
Responses
.3 −.10 .5 −.77*
Values are multiplied by 100 and rounded to the nearest integer. Val-
ues>0.4 are flaggedwith an*.
TABLE 4 Baseline performance on computerized FLAME











Mean SD Mean SD Mean SD
Speed of
Attention
97.60 19.4 92.56 14.80 90.02 17.3
Accuracy of
Attention
95.73 3.7 69.83 10.56 55.98 11.62
Memory 98.20 5.14 79.01 9.1 69.41 8.6
Executive
function
92.8 9.58 83.04 11.1 78.12 8.4
FLAME
Composite
96.40 6.81 77.61 9.83 61.08 9.36
6 DISCUSSION
The current article presents a longitudinal study of 1699 people with
neuropsychological impairments consistent with stage 2 or stage 3
early AD as part of a study of 10,000 people over the age of 50 from
PROTECT. The FLAME composite score covering four domains of
cognition, incorporating speed of attention, accuracy of attention,
TABLE 5 Differences in 2-year longitudinal change in the
progression of cognitive impairment between early dementia (stage 2)




stage 2 Early AD
Between-group
difference Normal vs









3.28 (1.73) 0.014 4.96 (1.72) 0.039
Accuracy of
Attention
12.23 (1.98) 0.000 21.84 (2.29) 0.000
Memory 11.48 (2.13) 0.000 19.23 (2.97) 0.000
Executive
Function
7.23 (1.32) 0.000 10.25 (2.12) 0.000
FLAME
Composite
6.41 (1.48) 0.007 8.19 (2.19) 0.009
memory, and executive function, was highly sensitive to longitudinal
change and predicted global decline over 2 years in people meeting
the study definition of early AD and MCI . This composite may offer
significant advantages for clinical trials enrolling older adults at
pre-dementia stages of the disease.
Themain goal of the current studywas to determinewhether a com-
puterized neuropsychologicalmeasurewasmore sensitive to change in
people with early AD or MCI than previously reported for traditional
tests. The neuropsychology composite uses widely used and well-
validated computerized neuropsychological tests. The specific compo-
nents of the FLAME composite were developed using baseline data
from all participants in the study, including those with normal cogni-
tion. The derived composite was then applied to examine longitudinal
decline in people with a level of cognitive impairment compatible with
stage 2 and stage 3 early AD, using the 2018 FDA framework,11 as a
validation cohort.
Grill et al.10 using the ADNI data set estimated thatmore than 1000
participants per arm would be required to detect a 25% treatment
effect with 80% power to 5% level of significance using the ADAS Cog
or MMSE. Using the same methodology, the FLAME computerized
neuropsychology composite gives required sample sizes per treatment
armofbetween119and205participants per treatment arm for clinical
trials focusing onearlyAD.Our findings suggest that this computerized
approach would benefit clinical trials by substantially enhancing sensi-
tivity to change. The FLAME composite can be conducted in the clinic,
or self-directed with participants at home. This potential flexibility
will give opportunities to repeat assessments more frequently without
significant additional cost, and the potential to complete all assess-
ments remotely may be particularly valuable under the challenge of
coronavirus disease 2019 (COVID-19) or future pandemics and may
also enable virtual monitoring of cognitive function in the community.
There are some limitations of the study.We developed operational-
ized study criteria for a level of cognitive and functional impairment
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TABLE 6 Change in performance over 2 years on the FLAME
a
composite and individual factors in people with stage 2 and stage 3 early AD and
potential power for clinical trials























3.54 3.18 27.35 0 404 3.62 4.32 14.32 0 726
Accuracy of
Attention
4.85 2.61 97.56 0 150 7.97 3.19 39.08 0 84
Memory 4.78 2.49 42.85 0 138 7.33 3.22 21.37 0 100
Executive
Function
2.94 2.08 90.22 0 250 3.09 2.23 27.94 0 266
FLAME
Composite
4.03 2.74 41.16 0.004 119 5.5 3.97 60.83 0.002 132
a
Factors of longitudinal, Attention,Memory, and Executive Function.
TABLE 7 Change in neuropsychological performance on the flame






















−1.52 1.48 70.43 <.0001 −0.38 480
Accuracy of
Attention
−3.17 2.97 4.9 0.0002 −0.79 446
Memory −3.28 2.43 2.37 0.0093 −0.82 278
Executive
Function
−1.93 2.14 5.26 0.014 −0.48 626
FLAME
Composite
−2.97 2.38 21.8 0.0016 0.74 328
compatible with stage 2 and stage 3 AD using the FDA framework, but
the nature of the study precluded the assessment of either Alzheimer’s
biomarkers (including amyloid) or cerebrovascular disease, which
are acknowledged as limitations. Studies in amyloid-positive indi-
viduals will be important for further validation, although based on
data using other cognitive assessments, sensitivity to change is likely
to be greater in these individuals.10,48 It should also be noted that
ADAS Cog was not evaluated in the current study, and therefore this
comparison is being made with published data from another cohort. It
will also be important to undertake comparisons with other evolving
composites such as PACC, Catch-Cog, and ADCOMS as further data
emerges from other studies of these potentially promising measures.
The neuropsychological tests incorporated in the composite used
TABLE 8 Change in neuropsychological performance on the




















−2.16 2.06 7.42 0.0057 −0.54 460
Accuracy of
Attention
−3.49 3.11 12.26 <.0001 −0.87 404
Memory −3.29 2.16 3.21 0.054 −0.82 220
Executive
Function
−1.73 2.41 7.24 0.0008 −0.43 990
FLAME
Composite
−2.41 2.19 16.54 0.0003 0.60 422
picture recognition as a key test of episodic memory, which is language
free, rather than word recall. The task utilizes similar picture pairs
(validated during the original test development), asking subjects to
distinguish the original from novel. The task always presented pictures
from the same 20 categories. Compared to verbal episodic memory
tasks, visual memory tasks reduce bias of language and education, thus
being advantageous for multi-center trials with diverse participants. It
should be acknowledged though that these assessments were based
on recognition and not verbal recall, as recall-based episodic memory
tasks are difficult to incorporate into remote computerized tools. The
breadthof domains incorporatedwithinFLAMEalsomake the compos-
ite potentially applicable for studies of non-ADormixed dementias and
conditions that typically produce cognitive profiles that heavily impact
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TABLE 9 Correlation between change in neuropsychological
performance on the FLAME composite and change in function (as





























Sig. (two-tailed) 0.001 0.003
attention, cognitive processing speed, and executive functions, such as
“subcortical” dementia, but further validation studies are needed.
7 CONCLUSION
FLAME is a sensitive measure of change in people with stage 2 and
stage 3 early dementia and MCI and provides a highly practical and
straightforward approach to improving power and reducing sample
size for clinical trials focusing on people with early AD, andwith poten-
tial utility for virtual monitoring of cognitive deficits in the community.
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